Geriatric assessment-driven intervention (GAIN) on chemotherapy toxicity in older adults with cancer: A randomized controlled trial.
Daneng Li(City Of Hope National Medical Center), William Dale(City of Hope), Marianna Koczywas(City Of Hope National Medical Center), Simone Fernandes Dos Santos Hughes(City of Hope), Vincent Chung(City of Hope), Enrique Soto‐Pérez‐de‐Celis(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Reena Jayani(Vanderbilt University Medical Center), Mina S. Sedrak(University of California, Los Angeles), Can‐Lan Sun(University of Minnesota), Arti Hurria(Unknown), Marwan Fakih(City of Hope), Kemeberly Charles(City of Hope), Monica Trent(University of California, Irvine Medical Center), Vani Katheria(City of Hope), Heeyoung Kim(City of Hope), Elsa Roberts(City of Hope), Cynthia M. Kelly(City of Hope), Leana Cabrera Chien(City of Hope), Jeanine Moreno(City of Hope), Joseph Chao(Amgen (United States))
Cited by 99
Related Papers
Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial
|The Lancet Oncology|2018|2.5k
Predicting Chemotherapy Toxicity in Older Adults With Cancer: A Prospective Multicenter Study
|Journal of Clinical Oncology|2011|1.8k
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|Journal of Clinical Oncology|2015|1k
American Cancer Society/American Society of Clinical Oncology Breast Cancer Survivorship Care Guideline
|CA A Cancer Journal for Clinicians|2015|737